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Abstract
Background
Different outcomes among patients hospitalized for bleeding after starting anticoagulation
could influence choice of anticoagulant. We compared length of hospitalization, proportion
of Intensive Care Unit (ICU) admissions, ICU length of stay, and 30- and 90-day mortality for
adults with atrial fibrillation hospitalized for bleeding after starting warfarin, dabigatran, or
rivaroxaban.
Methods
An US commercial database of 38 million members from 1 November 2010 to 31 March
2014 was used to examine adults with atrial fibrillation hospitalized for bleeding after starting
warfarin (2,446), dabigatran (442), or rivaroxaban (256). Outcomes included difference in
mean total length of hospitalization, proportion of ICU admissions, mean length of ICU stay,
and all-cause 30- and 90-day mortality.
Results
Warfarin users were older and had more comorbidities. Multivariable regression modeling
with propensity score weighting showed warfarin users were hospitalized 2.0 days longer
(95% CI 1.8–2.3; p < 0.001) than dabigatran users and 2.6 days longer (95% CI 2.4–2.9; p <
0.001) than rivaroxaban users. Dabigatran users were hospitalized 0.6 days longer (95% CI
0.2–1.0; p = 0.001) than rivaroxaban users. There were no differences in the proportion of
ICU admissions. Among ICU admissions, warfarin users stayed 3.0 days (95% CI 1.9–3.9;
p < 0.001) longer than dabigatran users and 2.4 days longer (95% CI 0.9–3.7; p = 0.003)
than rivaroxaban users. There was no difference in ICU stay between dabigatran and rivar-
oxaban users. There were no differences in 30- and 90-day all-cause mortality.
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Conclusions
Rivaroxaban and dabigatran were associated with shorter hospitalizations; however, there
were no differences in 30- and 90-day mortality. These findings suggest bleeding associated
with the newer agents is not more dangerous than bleeding associated with warfarin.
Introduction
The development of Non-vitamin K Oral Anticoagulants (NOACs) has provided an alternative
to warfarin for stroke prophylaxis in atrial fibrillation. Two widely used NOACs are dabiga-
tran, a direct thrombin inhibitor, and rivaroxaban, a factor Xa inhibitor. Two other factor Xa
inhibitors, apixaban and edoxaban, are also FDA-approved. The effectiveness and safety—
including incidence of bleeding—of each NOAC compared to warfarin have been studied in
randomized controlled non-inferiority trials.[1],[2],[3],[4]
One meta-analysis of these trials found that NOACs were associated with reduced inci-
dence of stroke, intracranial hemorrhage, and mortality but similar incidence of bleeding com-
pared to warfarin.[5] Two more recent analyses of clinical trials data found increased risk of
gastrointestinal bleeding on NOACs.[6],[7] Observational studies have demonstrated an
increased risk of bleeding with dabigatran compared to warfarin,9,10 and similar risks of bleed-
ing with rivaroxaban compared to warfarin.11,12
There has been little investigation to determine if NOAC-associated bleeding is more severe
or complicated than warfarin-associated bleeding. Most research has focused on intracranial
hemorrhage. One meta-analysis of trial data found NOACs to be associated with reduced mor-
tality and intracranial hemorrhage but that, after adjusting for site of bleeding, there was no
difference in incidence of fatal bleeding for any given bleeding site.[8] Observational studies
have found intracranial hemorrhage during NOAC therapy was associated with better radio-
graphic and functional outcomes.[9],[10] A detailed determination of the relative complexity
and severity of bleeding associated with these agents could help guide selection of oral antico-
agulants and management of acutely bleeding patients.
This study seeks to investigate the complexity and severity of NOAC-associated bleeding by
examining mean total length of hospitalization, proportion of patients admitted to the ICU,
mean length of ICU stay, and all-cause 30- and 90-day mortality for adults with atrial fibrilla-
tion who were hospitalized for bleeding after starting warfarin, dabigatran, or rivaroxaban.
Because warfarin is more easily reversible than newer agents, we hypothesized that, outside
of controlled trials, hospitalization for warfarin-associated bleeding may be associated with
shorter stays, fewer ICU admissions, and lower mortality.
Methods
Study design
We conducted a retrospective cohort study of patients with atrial fibrillation who were hospi-
talized for bleeding after starting warfarin, dabigatran, or rivaroxaban using administrative
claims data for outpatient, inpatient, and pharmacological treatments from the HealthCore
Integrated Research Environment (HIRE) from 1 November 2010 through 31 March 2014.
The HIRE database includes adjudicated medical and pharmacy claims data for approxi-
mately 38 million members of large commercial health plans in 14 US states. Patients with
missing pharmaceutical or medical claims were excluded. The database represents claims
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information from one of the largest commercially insured populations in the United States. To
ensure completeness of claims submissions, we allowed a 3-month runout period, based on
internal analyses indicating that virtually all claims become available within 3 months of an
event.
We included patients with atrial fibrillation who had filled a prescription for warfarin, dabi-
gatran, or rivaroxaban and were subsequently hospitalized for bleeding between 1 November
2010 and 31 March 2014. To ensure the accuracy of the indication for anticoagulation, the diag-
nosis of atrial fibrillation was defined as the presence of 2 medical claims (inpatient, emergency
department, and outpatient) with International Classification of Diseases, Ninth Revision (ICD9)
Clinical Modification codes of 427.31 or 427.3 (if no 5th digit) in the 6 month period before
starting one of the index drugs. We used ICD-9 codes to identify hospitalization for bleeding
based on previously described protocols with positive predictive values between 89 and 99%.
[11],[12],[13],[14],[15],[16] (S1 Appendix) To ensure that study participants were initiating antic-
oagulation, we excluded patients who had filled a prescription for any anticoagulant up to six
months prior to starting the index drug. Patients who had not filled their anticoagulation pre-
scriptions in the 60 days prior to hospitalization and those who had switched from one anticoag-
ulant to another prior to their index hospitalization were excluded. We also excluded patients on
rivaroxaban 10 mg (indicated only for venous thromboembolism prophylaxis), with a diagnosis
of severe renal disease, cardiac valve replacement, mitral valve disorder, antiphospholipid anti-
body syndrome, protein C deficiency, protein S deficiency, factor V Leiden syndrome, anti-
thrombin III deficiency, prothrombin 20210A mutation, nephrotic syndrome, paroxysmal
nocturnal hemoglobinuria, polycythemia vera, or essential thrombocytosis. (Fig 1, S1 Appendix)
Researchers had access only to a de-identified data set. Strict measures were taken to pre-
serve anonymity and confidentiality and to ensure full compliance with the 1996 Health Insur-
ance Portability and Accountability Act; as such, the study was deemed exempt from review by
the University of California San Francisco Institutional Review Board.
We identified death by discharge status within the HIRE database and by linking HIRE to
the Social Security Administration Death Master File Index through 31 April 2014. Data link-
age was confirmed using social security number and date of birth for more than 95% of sub-
jects in HIRE.
Outcomes
Outcomes included mean total length of hospital stay, proportion of patients admitted to the
ICU, mean length of ICU stay, and all-cause 30- and 90-day mortality. Due to limitations of
the data, we were unable to investigate transfusion of blood products or use of agents to reverse
warfarin.
Statistical analysis
We described baseline patient characteristics as means with standard deviations for normally
distributed continuous variables and proportions for categorical variables. We compared base-
line differences among patients in the three exposure groups using analysis of variance
(ANOVA) for continuous variables and the Pearson χ2 test for categorical variables. Statistical
analyses were conducted with SAS version 9.4 software (SAS Institute; Cary, NC).
We addressed confounding due to differences in baseline patient characteristics using mul-
tivariable Poisson regression models weighted by the inverse probability of treatment. This
was done in two steps.
First, we specified a multinomial logistic regression model to determine the probability of
starting warfarin, dabigatran, or rivaroxaban including age, sex, geographic region, chronic
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kidney disease, heart failure, coronary artery disease, myocardial infarction, ischemic stroke,
transient ischemic attack, peripheral vascular disease, cancer, diabetes, hypertension, dyslipi-
demia, pericarditis, hyperthyroidism, dementia, gait abnormalities, dizziness, diabetic and
alcoholic neuropathy, esophageal varices, major trauma, coagulation defect factors, and use of
the following medications: antiplatelet agents, antiarrhythmics, diuretics, vasopressors, ste-
roids, progestin, estrogen, proton pump inhibitors, amiodarone, ketoconazole, dronedarone,
nonsteroidal anti-inflammatory drugs (NSAIDs), and cyclooxygenase 2 (COX2) inhibitors as
predictors of treatment.[17] (S1 Appendix) Warfarin, the most commonly prescribed antico-
agulant, was selected as the reference drug.
Second, since the three propensity scores add up to one and are complementary, we calculated
the inverse weights for the treatment each patient received as the main variable to control for con-
founding. We assessed positivity by examining the distribution of the propensity scores for sub-
stantial overlap given the set of observed covariates. Balance achieved by the propensity scores was
assessed by comparing the three treatment groups on their baseline covariates using ANOVA,
which included the treatment groups weighted by the inverse probability of treatment received.
Fig 1. Cohort definition.
https://doi.org/10.1371/journal.pone.0193912.g001
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[18] (Table 1) After inverse propensity score weighting, only the prevalence of Parkinson’s disease
and cancer were significantly different among the three groups. Therefore, we included these
covariates in the multivariable models weighted by the inverse probability of treatment received.
Primary measures were analyzed as count data and proportions as appropriate.
We excluded patients if they discontinued anticoagulation (defined as a gap of> 60 days),
switched anticoagulants before or after the index admission, died, or lost health plan eligibility
prior to admission. We examined pairwise differences in mean total hospital stay among sub-
groups, which were identified a priori as patients with chronic kidney disease (stage 3 or
worse), heart failure, dementia, more than 7 comorbidities, those over 75 years of age, hemor-
rhagic stroke, major gastrointestinal bleeding, and those who restarted anticoagulation. We
defined restarting anticoagulation as a prescription fill of an index anticoagulant within 30
days of discharge from an inpatient stay due to bleeding. (Fig 2)
To determine the robustness of our results, we conducted several sensitivity analyses. First,
we sought to determined how conditions that might complicate anticoagulation or prolong
hospitalization affected our study by repeating the analysis with certain subgroups excluded,
including heart failure, chronic kidney disease (stage 3 or worse), 7 or more comorbid condi-
tions, hemorrhagic stroke and, major gastrointestinal bleeding, and those over 75 years of age.
Second, we explored an alternative analytic method by adjusting for the propensity scores of
dabigatran and rivaroxaban alone. [19],[20],[21],[22] (S2 Appendix) And third, because a
small but significant difference in the prevalence of cancer and Parkinson’s disease among the
three groups persisted after adjustment, we calculated the length of stay and mortality exclud-
ing patients with a Parkinson’s or cancer diagnosis. (S3 Appendix)
Results
Patient characteristics
The cohort consisted of 3,144 patients admitted for bleeding after starting anticoagulation for
atrial fibrillation. There were 2,446 warfarin users, 442 dabigatran users, and 256 rivaroxaban
users. (Fig 1)
Before propensity score weighting, warfarin users were more likely to be older, female, and
have heart failure, renal insufficiency, coronary artery disease, major trauma (including frac-
tures), peripheral vascular disease, diabetes mellitus, dementia, and gait abnormalities. After
propensity score weighting, there were significant differences between the groups only in the
prevalence of cancer (32.1% warfarin, 29.6% dabigatran, 31.6% rivaroxaban, p = 0.01) and Par-
kinson’s disease (1.4% warfarin, 0.9% dabigatran, 0.4%, p< 0.01). (Table 1)
Total length of hospital stay
Warfarin was associated with significantly longer hospitalizations for bleeding than either
dabigatran or rivaroxaban. Mean total length of stay was 7.9 days for warfarin users, 5.8 days
for dabigatran users, and 5.2 days for rivaroxaban users. Warfarin users were hospitalized 2.0
days longer (95% CI 1.8–2.3; p< 0.001) than dabigatran users and 2.6 days longer (95% CI
2.4–2.9; p< 0.001) than rivaroxaban users. Dabigatran users were hospitalized 0.6 days longer
(95% CI 0.2–1.0; p = 0.001) than rivaroxaban users. (Table 2)
ICU admission and length of stay
There were no significant differences in the proportion of patients admitted to the ICU among
the treatment groups, which occurred in 797 (33%) of warfarin users, 146 (33%) of dabigatran
users, and 76 (30%) of rivaroxaban users.
Bleeding during treatment with warfarin, dabigatran, or rivaroxaban
PLOS ONE | https://doi.org/10.1371/journal.pone.0193912 March 28, 2018 5 / 14
Table 1. Patient characteristics, unadjusted and propensity score weighted p-values, by treatment group.
Characteristic Warfarin
(n = 2503)
Dabigatran
(n = 461)
Rivaroxaban
(n = 260)
Unadjusted p-value Adjusted p-value
Age, mean (SD) yr 74.4 (11.0) 69.6 (12.6) 68.0 (12.5) <0.001 0.436
Male sex 55.7 61.8 62.9 0.009 0.635
Medicare Supplemental 11.1 12.2 7.4 0.133 0.406
Medicare Advantage 59.4 31.7 30.5 <0.001 0.243
Region
Missing 2.0 4.1 2.7
< 0.001 0.526Northeast 24.6 24.9 14.8
Midwest 47.4 35.1 34.8
West 11.0 14.5 18.8
South 15.1 21.5 28.9
Indexes
Deyo-Charlson Comorbidity Index, mean, (SD) 3.1 (2.6) 2.0 (2.0) 2.3 (2.3) <0.001 0.692
CHA2DS2-VASc, mean (SD) 4.6 (1.6) 3.8 (1.7) 3.8 (1.8) <0.001 0.561
Comorbid Illnesses
Ischemic stroke 11.9 10.4 11.7 0.668 0.403
Transient ischemic attack 3.7 4.5 3.1 0.607 0.215
Chronic kidney disease 22.6 9.8 12.9 <0.001 0.091
Myocardial Infarction 16.3 13.1 12.1 0.068 0.148
Heart Failure 46.8 35.3 35.9 <0.001 0.288
Cerebrovascular disease 20.2 16.5 15.6 0.058 0.266
Coronary artery disease 52.1 45.7 39.5 <0.001 0.383
Peripheral vascular disease 32.4 23.1 23.4 <0.001 0.080
Cancer 32.1 29.6 31.6 0.583 0.008
Osteoarthritis 29.0 21.9 23.0 0.002 0.281
Diabetes Mellitus 38.0 28.7 31.6 <0.001 0.316
Hypertension 94.2 93.2 91.0 0.106 0.865
Dyslipidemia 70.1 71.3 68.8 0.775 0.614
Pericarditis 1.1 1.6 1.2 0.667 0.426
Hyperthyroidism 2.0 2.0 0.4 0.165 0.880
Coagulation defect factors 7.0 2.9 3.9 0.002 0.192
Dementia 4.7 2.7 1.2 0.004 0.405
Parkinson’s disease 1.4 0.9 0.4 0.360 <0.001
Gait Abnormality 10.4 3.6 7.0 <0.001 0.496
Dizziness 12.8 14.3 12.1 0.654 0.479
Diabetic and alcoholic neuropathy 3.1 2.0 2.0 0.373 0.344
Esophageal varices 0.3 0.2 0.0 1.000 0.504
Major trauma 23.0 15.6 18.4 <0.001 0.116
Pre-Index Medications
Antiarrhymics 10.3 16.5 22.3 <0.001 0.646
Amiodarone 5.9 7.0 10.5 0.013 0.511
Diuretics 44.4 39.8 34 0.002 0.168
Vasopressors 0.4 0.2 1.2 0.120 0.926
Antihyperlipidemics 48.1 53.6 48.4 0.102 0.191
NSAIDs 9.8 11.3 13.7 0.119 0.629
COX2 Inhibitors 1.3 1.1 1.2 1.000 0.613
Platelet aggregation inhibitors 13.4 13.1 16.8 0.298 0.066
(Continued)
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Among patients admitted to the ICU, mean length of ICU stay was 10 days for warfarin
users, 7.5 days for dabigatran users, and 8.0 days for rivaroxaban users. Warfarin was associ-
ated with a 3.0 day longer stay (95% CI 1.9–3.9; p =<0.001) compared to dabigatran and a 2.4
day longer stay (95% CI 0.9–3.7; p = 0.003) compared to rivaroxaban. Mean ICU stay was not
significantly different between dabigatran and rivaroxaban. (Table 2)
30- and 90-day all-cause mortality
All-cause mortality 30 days after discharge was 7.1% among warfarin users, 8.0% among dabi-
gatran users, and 4.6% among rivaroxaban users. After 90 days, the rates were 9.2% among
warfarin-users, 9.7% among dabigatran users, and 5.0% among rivaroxaban users. There were
no significant differences in relative risk of all-cause 30- or 90-day mortality among the three
groups. (S4 Appendix)
Subgroup analyses
Warfarin was associated with longer hospital stays in every subgroup examined. Warfarin is
known to be associated with increased risk of intracranial hemorrhage; however, after exclud-
ing patients with intracranial hemorrhage, warfarin was still associated with significantly lon-
ger hospitalization. Titration of warfarin dose before discharge may prolong hospitalizations;
however, warfarin was also associated with longer hospital stay in patients who discontinued
anticoagulation and therefore did not require warfarin titration before discharge. In subgroup
analyses, there were no consistent differences in length of stay between patients using dabiga-
tran and rivaroxaban. (Fig 2)
Sensitivity analyses
Repeating our analysis with the exclusion of certain subgroups with conditions that might pro-
long hospitalization or increase mortality did not significantly change outcomes; these sub-
groups included heart failure, chronic kidney disease (stage 3 or worse), 7 or more comorbid
conditions, hemorrhagic stroke and, major gastrointestinal bleeding, and those over 75 years
of age.
Outcomes did not significantly change when we applied alternative analytic methods by
adjusting for the propensity scores of dabigatran and rivaroxaban alone. (S2 Appendix)
Finally, repeating the analysis with the exclusion of patients with either Parkinson’s or can-
cer diagnosis again suggested the robustness of our findings (S3 Appendix)
Table 1. (Continued)
Characteristic Warfarin
(n = 2503)
Dabigatran
(n = 461)
Rivaroxaban
(n = 260)
Unadjusted p-value Adjusted p-value
Other antiplatlets 2.1 2.0 3.1 0.504 0.300
Anti-inflammatory agents 0.1 0.7 0.8 0.008 0.996
Steroids 19.1 17.0 25.4 0.021 0.438
Progestin 0.5 0.0 0.8 0.209 0.369
Estrogen 1.1 1.4 3.1 0.029 0.317
Dronedrone 0.9 3.6 3.5 <0.001 0.948
Ketoconazole 1.5 1.8 0.8 0.572 0.432
Proton pump inhibitor 24.0 24.2 29.3 0.175 0.590
https://doi.org/10.1371/journal.pone.0193912.t001
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Fig 2. Differences in adjusted mean total length of stay.
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Discussion
We found that admission for bleeding during dabigatran or rivaroxaban therapy was associ-
ated with shorter total hospital stay and shorter ICU stay compared to admission for bleeding
during treatment with warfarin. We found no difference in mortality among the groups but
rather a 90-day mortality range of 5.0% to 9.7% that is consistent with those of previously stud-
ies,[23],[24],[25],[26] and identifies a vulnerable patient population with post-discharge mor-
tality comparable to that in heart failure.[27]
This study did not confirm our hypothesis that, because anticoagulation with warfarin is
more easily reversible, admission for bleeding during warfarin therapy would be associated
with shorter hospital stays, fewer ICU admissions, and lower mortality. We considered several
hypotheses as to why warfarin might be associated with longer hospital stays.
First, we considered the possibility that warfarin’s known association with increased risk of
intracranial hemorrhage was responsible for the prolonged hospitalizations; however, the asso-
ciation of warfarin with prolonged hospitalization persisted after excluding patients with intra-
cranial hemorrhage.
Second, we entertained the possibility that prolonged hospitalization may be due to the
need to titrate warfarin before discharge. Alternately the logistical challenges of outpatient
warfarin treatment—such as bridging therapy or scheduling in anticoagulation clinic—may
have delayed discharge. However, even among patients who discontinued anticoagulation at
discharge, warfarin was associated with longer hospitalization. Among patients restarting
anticoagulation, warfarin’s association with prolonged hospitalization was stronger, suggesting
https://doi.org/10.1371/journal.pone.0193912.g002
Table 2. Mean adjusted length of stay, ICU admission, & discontinuation.
Mean Adjusted Total Length of Hospital Stay
Warfarin
(n = 2446)
Dabigatran
(n = 442)
Rivaroxaban
(n = 256)
Unadjusted Mean Total Length of Hospital stay, (SD) 8.9 days (14.14) 6.5 days (7.95) 5.8 days (6.64)
Adjusted Mean Total Length of Hospital Stay 7.9 days 5.8 days 5.3 days
Difference in Adjusted Mean Total Length of Hospital Stay
LOS, (95% CI)
Warfarin vs. Dabigatran 2.0 days (1.8–2.3, p < 0.001)
Warfarin vs. Rivaroxaban 2.6 days (2.4–2.9, p < 0.001)
Dabigatran vs. Rivaroxaban 0.6 days (0.2–1.0, p < 0.001)
ICU Admission and Length of ICU Stay
Patients with ICU stay 33% 33% 30%
Unadjusted Mean ICU Length of Stay (SD) 9 days (12.08) 6.9 days (6.71) 7.1 days (7.63)
Adjusted Mean ICU Length of Stay 10.0 days 7.5 days 8.0 days
Difference in Adjusted Mean Total ICU Stay among Patients with ICU admission
LOS, (95% CI)
Warfarin vs. Dabigatran 3.0 days (1.9–3.9, p < 0.001)
Warfarin vs. Rivaroxaban 2.4 days (0.9–3.7, p = 0.003)
Dabigatran vs. Rivaroxaban 0.6 days (-1.2–2.0, p = 0.490)
Discontinuation of Anticoagulation
Discontinuation of anticoagulation, 37.7% 33.7% 41.4%
https://doi.org/10.1371/journal.pone.0193912.t002
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that the need to titrate warfarin dose and devise appropriate follow up may contribute to the
increased medical complexity of warfarin-associated bleeding in some patients.
There are several possibilities why reversibility does not lead to shorter hospitalizations and
mortality from bleeding. One explanation may be that reversal of warfarin may not occur rap-
idly enough to confer benefit compared to the shorter half-life of dabigatran and rivaroxaban.
Alternately, clinicians may not recognize the need for reversal of warfarin soon enough to
change outcomes, or reversal may be clinically meaningful only in subgroups—such as major
trauma—not examined in this study.
Our finding that admission for bleeding during reversible anticoagulation was no shorter
than admission for bleeding during irreversible anticoagulation raises the potential that clini-
cians may be too focused on reversibility rather than on the overall safety profile of a drug.
Determining the appropriate role of anticoagulation reversal will become increasingly impor-
tant given the FDA accelerated approval of idarucizumab—a monoclonal reversal agent for
dabigatran—and the publication of a trial showing that andexanet alfa can effect physiologic
reversal of rivaroxaban-induced anticoagulation.[28] Andexanet alfa is currently being consid-
ered for FDA approval under the “breakthrough therapy” pathway.
The significant risk of mortality after admission for both warfarin- and NOAC-associated
bleeding underscores the need for further research into the complexity, severity, and treatment
of bleeding during oral anticoagulation. Particular attention should be paid to the newest oral
anticoagulants and how associated bleeding is affected by transfusion of blood products and
the use of reversal agents.
Study limitations
This study examines outcomes after bleeding has occurred, not the risk of bleeding during
anticoagulation with warfarin or NOACs. This study is also subject to the well-known limita-
tions of medical claims analysis, particularly a lack of granularity of in some aspects of the
data. For example, identification of a hospitalization for hemorrhage relied upon the use of
one of the relevant ICD-9 codes in the insurance claim. Similarly it was not possible to deter-
mine if certain comorbidities arose before or during the hospitalization for hemorrhage. How-
ever, while the absence of granularity is regrettable, these limitations should affect all three
treatment groups in a non-differential manner. Other limitations include the observational
design and an inability to capture fatal bleeding before admission.
Importantly, warfarin users were significantly older and sicker, and despite careful adjust-
ments, this disadvantage may have accounted for the observed differences in outcomes. How-
ever, the many sensitivity analyses we undertook demonstrated robust results. Moreover, the
marked differences in length of stay after statistical adjustment for a large number of variables
make it unlikely that the observed differences in outcomes are purely the result of residual con-
founding. Finally, our results are consistent with clinical trial data. An analysis of the RE-LY
trial found that patients admitted for major bleeding while on dabigatran had shorter ICU
stays and no difference in mortality when compared to patients admitted for major bleeding
on warfarin.[29] An analysis of the ROCKET-AF trial found that patients who experienced
major bleeding during rivaroxaban therapy had no difference in all-cause mortality compared
to those with major bleeding on warfarin.[30]
Notably, our study found a lower all-cause 30-day mortality than that previously described
in the trial data. An analysis of ARISTOTLE trial found no difference in 30 day all-cause mor-
tality for patients on either apixaban or warfarin who had major bleeding events.[31] However,
that study noted a 30 day mortality of 14.9%, which contrasts to far lower 4.6–8.0% noted in
our study. This discrepancy is likely the result of two factors. First, ARISTOTLE was a
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multinational trial in which Russia, Argentina, Ukraine, and China were among the top six
enrolling countries; therefore, it is expected that our study of insured Americans would have a
lower 30 day all-cause mortality. Second, trial registries may more completely capture mortal-
ity than retrospective interrogation of discharge status and linkage to the Social Security
Administration Death Master File.
It must be noted that the Death Master File made a change in how it disclosed its mortality
in November 2011that may have resulted in underreporting of mortality[32]. Because our
study started on 1 November 2010 with dabigatran’s entry into the market, and because rivar-
oxaban was not FDA approved until 4 November 2011, this introduces the possibility for a dif-
ferential capture of mortality. Therefore, we conducted a sensitivity analysis on the mortality
findings by restricting data from 1 November 2011 to 31 March 2014 and found no significant
change. (S5 Appendix)
It is possible that the differences in length of stay may be caused by differential admission
and treatment of bleeding during oral anticoagulation. We were unable to examine clinician
decision-making at the time of admission or the use of blood products and reversal agents. It is
possible that clinicians were more wary of dabigatran- and rivaroxaban-associated bleeding
and therefore had a lower threshold for admission; however, equal proportions of each treat-
ment group were admitted to the ICU, suggesting comparability. While we were unable to
compare blood product transfusions, analysis of RE-LY data found that patients admitted with
major bleeding during dabigatran therapy receive more transfusions of red blood cells than
those admitted for major bleeding during warfarin therapy.[29]
Conclusions
Rivaroxaban and dabigatran were associated with shorter hospitalizations; however, there
were no differences in 30- and 90-day mortality. These findings suggest bleeding associated
with the newer agents is not more dangerous than bleeding associated with warfarin.
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